Citi reiterates buy rating on Arcus Biosciences after stock drops 20%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Form 424B5 Arcus Biosciences, Inc.
October 21, 2026 4:30 PM EDTTable of Contents
The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in... More
Form 8-K Arcus Biosciences, Inc. For: Oct 21
October 21, 2026 4:10 PM EDTfalse 0001724521 0001724521 2026-10-21 2026-10-21... More



